Abstracts and Awards – Vascular Discovery 2025
Marriott Baltimore Waterfront | Baltimore, Maryland
Abstract Submission Guidelines
Abstract Submission is closed for 2025
Rules and Guidelines for Abstract Submission
NEW Submission deadline: December 2, 2024 at 6:00 p.m CT
To ensure that your abstract receives proper scientific consideration, be sure to submit to the appropriate category.
Abstract Submission:
- Review Best Practice for Writing Abstracts
- Submit all abstracts in English.
- Authors should not "split" data to create several abstracts from one. If splitting is judged to have occurred, priority scores of related abstracts will be reduced.
- Abstracts containing identical or nearly identical data submitted from the same institution and/or individuals will be disqualified.
- Proofread abstracts carefully to avoid errors before submission. The abstract will be reviewed exactly as submitted.
- An abstract must have a short, specific title (containing no abbreviations) that indicates the nature of the investigation.
- Describe briefly the objectives of the study unless they are contained in the title. Include a brief statement of methods if pertinent. State findings in detail sufficient to support conclusions. Abstracts should not describe research in which the chemical identity or source of the reagent is proprietary or cannot be revealed.
- Use generic drug names.
- Do not begin sentences with numerals.
- Standard abbreviations may be used without definition. Nonstandard abbreviations (kept to a minimum) must be placed in parentheses after the first use of the word or phrase abbreviated.
- Do not include references, credits or grant support.
- Do not include the names or personal information of any patient participating in the study or trial.
- Abstracts are limited to 2,500 characters (or about 400 words). The character limit cannot exceed 2,500. Spaces and punctuation count as characters.
Acceptance:
- Submitters will be notified of acceptance/non-acceptance status via e-mail by early January 2025.
- Abstracts are reviewed in blinded fashion and selected on the basis of scientific merit. The conference Program Committees will determine whether the abstract is to be presented orally or by poster.
- Request oral or poster presentation on the properties tab of the submitter site (note that poster presentations may be selected for a moderated poster). Unless you select “poster only” the selection of one of these options will neither prejudice acceptance nor guarantee an oral or moderated poster presentation because abstracts will be arranged to fit into a thematic group for presentation. Although every effort will be made to accommodate your presentation request, there is no guarantee that you will present in the mode of your preference.
- Expenses associated with the submission and presentation of an abstract are the responsibility of the presenter.
- Presenting/submitting authors must register and pay associated fees for attendance at the conference.
- Abstracts selected will be published in an online version of the ATVB Journal.
- Accepted abstracts will not have been published (manuscript or abstract) prior to the date of this submission or presented at any national or international meeting prior to April 22, 2025. Abstracts are embargoed for release at date and time of presentation or time of AHA news event. Information may not be released before then. Failure to honor embargo policies will result in the abstract being withdrawn and barred from presentation.
- Submission of an abstract constitutes a commitment by the authors to present if accepted. Failure to present, if not justified, will jeopardize future acceptance of abstracts.
- Recording Policy:
- Unauthorized recording of AHA Scientific Sessions, scientific conferences and the ASA International Stroke Conference is prohibited, whether by video, still or digital photography, audio or any other recording or reproduction mechanism. This includes recording of presentations and supporting audiovisual materials and of poster presentations and supporting poster materials.
- The American Heart Association and American Stroke Association reserve the rights to all recordings or reproductions of presentations at AHA/ASA scientific conferences and meetings.
Abstract Withdrawal:
- There is no guarantee that your abstract will not be published in the final program and the Journal unless request for withdrawal is received in writing by 5:00 PM CST February 21, 2025.
Abstract Revisions:
- Proofread abstracts carefully to avoid errors before submission. No proof pages will be sent to authors.
- Abstracts may not be revised after 6:00 PM CDT, December 2, 2024.
Presentation:
- All presentations and question-and-answer sessions will be conducted in English. Presenters may request assistance from the moderator who will repeat or rephrase questions from the audience or may ask a colleague in the audience to assist with translation.
- References to work previously published by other authors must include citations at the bottom of the appropriate slides.
- Unauthorized recording of the conference is prohibited, whether by video, still or digital photography, audio or any other recording or reproduction mechanism. This includes recording of presentations and supporting AV materials and of poster presentations and supporting poster materials.
- All oral presentations must be in electronic format. Electronic presentations must be submitted 12 business hours in advance of the session start time. Instructions will be provided upon acceptance.
Please review the categories below including any definitions. You must select at least one primary category and will have the option to select an additional secondary category. Abstract sessions are typically arranged thematically. Category selection helps guide the selection of abstracts according to topic.
- Aortic Aneurysm Disease
- Apolipoproteins and Lipid Metabolism
- Blood Coagulation, Platelet Function and Antithrombotic Therapy
- Cardio-oncology – the Role for the Vasculature
- Cardiovascular Precision Medicine
- COVID-19
- Functional Genomics and Epigenetics in Vascular Disease
- Immune Mechanisms of Atherosclerosis
- Immunity and Inflammation in Vascular Biology
- Metabolic Disorders and Atherosclerosis
- Molecular and Cellular Mechanisms of Atherosclerosis
- Molecular, Developmental and Cellular Biology of Vessel Wall
- Peripheral Artery Disease, Carotid Artery Disease and Stroke
- Population Science and Genetics in Vascular Discovery
- Sex Differences in Cardiovascular Disease
- Therapeutic Targets in Atherosclerosis
- Venous Thromboembolism and Lymphatic Disease
Best Practices
The suggestions below are intended to provide guidance on abstract writing.
Title
To the extent the data permits, make the title dynamic and conclusive, rather than descriptive. For example, "Hypoxia Inhibits Kv1.5 Channels in Rat Pulmonary Artery Smooth Muscle Cells" is preferable to "Effects of Hypoxia on Kv1.5 Channels." Explicit titles denoting the findings should be used (not "Investigations of…," "Studies of…," etc.)
Structure
Abstracts should have the following identifiable sections: Introduction, Hypothesis, Methods, Results and Conclusions.
Abbreviations
Abbreviations may be used after they are spelled out or defined. Use generic, not commercial, names for all therapeutic agents.
Category
Be sure to select the correct abstract category. Category selection determines which team grades the abstract. If you select the appropriate category, your abstract will be blindly graded by experts familiar with the science of the category.
Common mistakes
- Failure to state the hypothesis. We advise a formal statement such as, "We assessed the hypothesis that…"
- Failure to state a conclusion. We encourage a final sentence that says: "In conclusion…"
- Failure to state sample size. The reviewers want to assess the quality of the data – they need a mean SEM and a sample size.
- Excessive use of abbreviations. All but the most standard abbreviations should be defined, and most abstracts should have less than 3 abbreviations.
Traps to avoid
- Typographical errors
- References cited in the abstract
- Not providing context or a statement of relevance that provides the rationale for your study.
- Complex graphics. Simple line or bar graphs are most appropriate. Ensure the font size is adequately large on each axis to be visible. Check a printed version of the abstract before submitting.
- Duplicative work
Remember: Make sure your abstract is clear, concise, and follows all rules. Show your abstract to a colleague prior to submission and modify accordingly. A fresh pair of eyes will help spot any errors and will ensure the final package is ready for submission.
Awards Offered for 2025
The Councils on Arteriosclerosis, Thrombosis and Vascular Biology (ATVB) and Peripheral Vascular Disease (PVD) proudly sponsor the awards listed below in association with the Vascular Discovery conference and invite their members to apply. Detailed criteria for each award is located on the conference website. Information is also listed on the abstract submission website.
All required materials must be submitted through the abstract submission site prior to the deadline. Incomplete award applications will not be considered.
To qualify for these awards, you must meet the following deadlines:
- November 25, 2024 – Deadline to have an active AHA membership with the Council on Arteriosclerosis, Thrombosis, and Vascular Biology, or the Peripheral Vascular Disease (PVD) Council.
- December 2, 2024, 6:00 p.m. Central Time – Deadline to submit your science to Vascular Discovery: From Genes to Medicine 2025 and apply for these awards.
Awards offered by the Council on Arteriosclerosis, Thrombosis, and Vascular Biology (ATVB)
Awards offered by the Council on Peripheral Vascular Disease (PVD)
Paul Dudley White International Scholar Award
Abstracts submitted to the Vascular Discovery 2025 Scientific Sessions may be considered for a Paul Dudley White International Scholar Award. This award recognizes authors that contributed to the highest ranked accepted abstract from each country. You don't have to apply, and professional membership is not required.
The presenting author will be notified of award selection approximately 6 weeks prior to the meeting. Interested in knowing more? Visit the Paul Dudley White International Scholar Award web page.
Special Recognition Awards
To qualify for these Vascular Discovery: From Genes to Medicine Scientific Sessions awards you must meet the following deadlines.
- November 28, 2024– Deadline to have an active AHA membership with the council sponsoring the award.
- December 2, 2024, 6 p.m. CT – Deadline to apply for awards requiring submission in the Council Awards Application System.
Mentoring Awards
- ATVB Diversity and Inclusion Leadership Recognition Award
- The ATVB Women’s Leadership Committee Award for Outstanding Mentorship of Women
Mid-Career Awards
- Jeffrey M. Hoeg Arteriosclerosis, Thrombosis, and Vascular Biology Award for Basic Science and Clinical Research
- PVD Mid-Career Lecture
Important
The AHA has moved to a single sign-on process for submitting abstracts and disclosures through our website, Professional Heart Daily.
- Abstract submitters must have a username and password on professional.heart.org to complete their abstract submission when submitting to any AHA scientific meeting.
- If you do not remember your Professional Heart Daily login information or need to update your personal profile, do not create a new account. Please reach out to AHA Customer Service for assistance:
- The AHA is now required to collect financial disclosures for all abstract submitting authors and co-authors
- As the submitting author, please be prepared to provide all co-author emails.
- Co-authors without a complete disclosure will receive separate correspondence to submit this information.
AHA Customer Service:
1-888-242-2453 (Inside U.S.)
1-214-570-5935 (Outside U.S.)
Email: [email protected]
Hours of Operation: Monday-Friday (8 a.m. – 5 p.m. CT)